What are the key takeaways from this Business Of Biotech episode?

Key insights include: **Royalty-weighted deal structure:** When negotiating partnerships, prioritize downstream royalties and milestones over headline upfront payments. Zymeworks accepted $375M upfront from Jazz in 2022 — equal to its entire market cap at the time — while retaining royalty rights that became substantially more valuable after zanadetimab's FDA accelerated approval and positive Phase 3 gastric cancer data in 2024.; **Open-access platform validation strategy:** Rather than partnering exclusively with one pharma company, Zymeworks licensed its Azymetric design platform non-exclusively to multiple partners — GSK, Lilly, Daiichi Sankyo, J&J — retaining financial stakes in each resulting product. J&J's pazritamig, designed on Azymetric, has now entered multiple Phase 3 trials, generating milestone payments without Zymeworks funding development.; **China partnership for clinical scale:** To access HER2-expressing gastric cancer patient populations in Asia, Zymeworks partnered with BioGene (now BioNTech subsidiary B1) in 2017 specifically for China clinical operations — a market where running independent trials is operationally prohibitive. This accelerated zanadetimab's global development timeline and secured commercial coverage across three continents via two partners.

What did Zymeworks' Kenneth Galbraith discuss on Business Of Biotech?

Kenneth Galbraith, CEO of Zymeworks, explains how the company built a portfolio of five pharma partnerships using its Azymetric bispecific antibody platform, secured a $375M Jazz Pharmaceuticals deal for zanadetimab, and pivoted in November 2024 toward a hybrid royalty acquisition model to compound returns without building internal commercialization infrastructure. Key topics include: **Royalty-weighted deal structure:** When negotiating partnerships, prioritize downstream royalties and milestones over headline upfront payments. Zymeworks accepted $375M upfront from Jazz in 2022 — equal to its entire market cap at the time — while retaining royalty rights that became substantially more valuable after zanadetimab's FDA accelerated approval and positive Phase 3 gastric cancer data in 2024.; **Open-access platform validation strategy:** Rather than partnering exclusively with one pharma company, Zymeworks licensed its Azymetric design platform non-exclusively to multiple partners — GSK, Lilly, Daiichi Sankyo, J&J — retaining financial stakes in each resulting product. J&J's pazritamig, designed on Azymetric, has now entered multiple Phase 3 trials, generating milestone payments without Zymeworks funding development..

How long is this episode of Business Of Biotech?

This episode is 58 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Business Of Biotech

A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith

January 12, 2026

58 min episode · 2 min read

Zymeworks' Kenneth Galbraith

Episode

58 min

Read time

2 min

Topics

Career Growth, Productivity, Relationships

AI-Generated Summary

Published Mar 14, 2026

Key Takeaways

✓Royalty-weighted deal structure: When negotiating partnerships, prioritize downstream royalties and milestones over headline upfront payments. Zymeworks accepted $375M upfront from Jazz in 2022 — equal to its entire market cap at the time — while retaining royalty rights that became substantially more valuable after zanadetimab's FDA accelerated approval and positive Phase 3 gastric cancer data in 2024.
✓Open-access platform validation strategy: Rather than partnering exclusively with one pharma company, Zymeworks licensed its Azymetric design platform non-exclusively to multiple partners — GSK, Lilly, Daiichi Sankyo, J&J — retaining financial stakes in each resulting product. J&J's pazritamig, designed on Azymetric, has now entered multiple Phase 3 trials, generating milestone payments without Zymeworks funding development.
✓China partnership for clinical scale: To access HER2-expressing gastric cancer patient populations in Asia, Zymeworks partnered with BioGene (now BioNTech subsidiary B1) in 2017 specifically for China clinical operations — a market where running independent trials is operationally prohibitive. This accelerated zanadetimab's global development timeline and secured commercial coverage across three continents via two partners.
✓Hybrid capital allocation model: Zymeworks now allocates capital across three parallel tracks: internal R&D focused on trispecific antibodies and ADCs, external asset acquisition for in-house development and re-partnering, and direct royalty stream purchases on late-stage assets invented and licensed by others. Hiring a Chief Investment Officer in November 2024 signals the royalty acquisition track is being built as a distinct business unit.
✓Ten-year development cycle management: Biotech leaders must plan for capital market cycles, talent retention, and partner focus shifts that rarely align with decade-long drug development timelines. Galbraith recommends structuring partnerships and financial arrangements to accommodate investor liquidity needs mid-cycle, rather than assuming continuous capital availability — a lesson drawn from building QLT into a two-product global company over 13 years.

What It Covers

Kenneth Galbraith, CEO of Zymeworks, explains how the company built a portfolio of five pharma partnerships using its Azymetric bispecific antibody platform, secured a $375M Jazz Pharmaceuticals deal for zanadetimab, and pivoted in November 2024 toward a hybrid royalty acquisition model to compound returns without building internal commercialization infrastructure.

Key Questions Answered

•Royalty-weighted deal structure: When negotiating partnerships, prioritize downstream royalties and milestones over headline upfront payments. Zymeworks accepted $375M upfront from Jazz in 2022 — equal to its entire market cap at the time — while retaining royalty rights that became substantially more valuable after zanadetimab's FDA accelerated approval and positive Phase 3 gastric cancer data in 2024.
•Open-access platform validation strategy: Rather than partnering exclusively with one pharma company, Zymeworks licensed its Azymetric design platform non-exclusively to multiple partners — GSK, Lilly, Daiichi Sankyo, J&J — retaining financial stakes in each resulting product. J&J's pazritamig, designed on Azymetric, has now entered multiple Phase 3 trials, generating milestone payments without Zymeworks funding development.
•China partnership for clinical scale: To access HER2-expressing gastric cancer patient populations in Asia, Zymeworks partnered with BioGene (now BioNTech subsidiary B1) in 2017 specifically for China clinical operations — a market where running independent trials is operationally prohibitive. This accelerated zanadetimab's global development timeline and secured commercial coverage across three continents via two partners.
•Hybrid capital allocation model: Zymeworks now allocates capital across three parallel tracks: internal R&D focused on trispecific antibodies and ADCs, external asset acquisition for in-house development and re-partnering, and direct royalty stream purchases on late-stage assets invented and licensed by others. Hiring a Chief Investment Officer in November 2024 signals the royalty acquisition track is being built as a distinct business unit.
•Ten-year development cycle management: Biotech leaders must plan for capital market cycles, talent retention, and partner focus shifts that rarely align with decade-long drug development timelines. Galbraith recommends structuring partnerships and financial arrangements to accommodate investor liquidity needs mid-cycle, rather than assuming continuous capital availability — a lesson drawn from building QLT into a two-product global company over 13 years.

Notable Moment

Galbraith reveals that when Zymeworks first approached Merck to validate its Azymetric platform around 2007, Merck handed over a project they had already failed internally — with little expectation the small Vancouver company would succeed. That successful result became the proof point used to open partnerships with GSK, Lilly, Daiichi Sankyo, and J&J.

Know someone who'd find this useful?